Emma holds 18 years of life science experience whereof 16 from leading market access, reimbursement, outcomes research, health economics and real-world evidence registry studies in the academic and consultancy setting. She established and managed for 12 years the Nordic Access consulting team of Heron Evidence Development which later became part of the international CRO firm Parexel. Most recently, Emma was also assigned the global Access consulting operations and development lead role, where she was driving professional development programs, operational processes and business-growth strategies for Parexel. Emma is affiliated to the Karolinska Institutet and prior to consulting she was working in clinical practice, as a physician. Emma is an expert in market access strategy development, reimbursement dossier development and submission in Sweden, Norway, Denmark and Finland and holds specific TA expertise in immuno-oncology, oncology, neurology, orphan diseases, cell and gene therapy. She holds and MD from Karolinska Institutet and a MSc in Economics from Stockholm University. Emma is also a PhD candidate at the Unit for Health Economics and Policy at the Department of LIME at Karolinska Institutet LIME Dept.

Åsa has accumulated 20 years of experience across multiple functional roles in the pharmaceutical industry and consultancy. She brings a holistic view on life science, including strategy, commercial and access opportunities, and generation of data to support successful launch and reimbursement processes. In 2021 Åsa cofounded Macanda to build a more senior consultancy focusing on complex products. In her previous role she headed up the Nordic HEMAR team at Janssen, which was responsible for pipeline and established brands as well as health economics and market access of focus products, mostly in the specialist segment. She was also a member of Janssen’s European Early HTA Advice Committee. In addition, Åsa has experience as Commercial Director for oncology and specialist products, Launch Lead, Health Economics Team Lead and Manager for CNS and vaccines from close to 5 years at each of Pfizer and GSK. Her background also includes being the CEO for international health-economics consultancy Quantify Research, developing and leading their growth journey while in parallel providing strategic market access advice, leading multiple reimbursement submissions in the Nordics and supporting real-world evidence projects. Åsa holds a Master’s degree in International Economics from Stockholm School of Economics.

Emma is an expert in health economic modelling and data analytics. She has 10 years’ experience in health economics, modelling, real-world evidence studies, and access projects from international consultancy and academia. She has accumulated broad skills in various areas such as observational study design, advanced data analysis and statistics, programming, model design, and reimbursement submissions. Prior to co-founding Macanda in 2021, Emma worked in senior lead analyst roles; leading and overseeing research and analytical work in consultancy setting. Emma holds a masters degree in Economics from Uppsala University and is an affiliated researcher at the Department of Learning, Informatics, Management and Ethics at Karolinska Institutet. Her research has covered methods such as modelling and statistical analysis of observational data.

Josefine’s background includes six years of experience from life science, with roles in health economics consultancy and global pharmaceutical companies. She is a statistical scientist specialized in health economic modelling, programming, machine learning, big data analytics and real-world evidence. In her previous employment at SOBI she was responsible for statistical analysis in clinical trials and observational studies. She has also worked as Senior Research Analyst at Quantify Research, supporting Nordic reimbursement applications, development of global health-economic models and literature reviews. She has experience in multiple disease areas including oncology, CNS, haemophilia, and orphan diseases. Josefine holds a BSc in Mathematics with a profile in Computational Biology from Stockholm University and a MSc in Applied and Computational Mathematics from KTH (Royal Institute of Technology). Her bachelor thesis work was to build a simulation model for analysis of NGS data in collaboration with SciLifeLab and her master thesis work was to develop a machine learning model for liver cancer diagnostics in collaboration with Moderna and Karolinska Institutet.

Marcus has more than 14 years of life science experience of which the latest 9 years have been in market access consulting. Marcus is an expert in market access strategy development, health economics, and Nordic reimbursement. Over the years Marcus has worked in a wide range of disease areas, many of them have been rare conditions. Marcus has also supported the launch of ATMPs in the Nordics, including both cell- and gene therapies. Before joining Macanda Marcus was a senior director at Parexel access consulting where he developed a focus on Nordic access and reimbursement through supporting clients with prescription drugs and hospital products in all Nordic countries. Prior to joining Parexel Marcus was the CEO of a medical device company and held several positions in life science consulting in Switzerland and the US. Marcus has a MSc in Industrial Management from Linköping University/ETH Zürich with a specialization in strategy.

Jonas has more than 17 years of experience from health technology assessment and market access in the Nordics, including 12 years at HTA agencies. Prior to joining Macanda he was a principal consultant at Parexel leading client engagements in the Nordics. Jonas has extensive experience from reimbursement applications in the Nordics for prescription drugs as well as hospital drugs, including orphan drugs and cell & gene therapies. Jonas has a MSc and a PhD in Pharmacology, Uppsala University.

Chantelle holds 6 years of experience in conducting epidemiological studies with Swedish register data including several population-based cost-of-illness studies. In this, she has developed analytical capabilities including statistical analysis of observational data, scientific writing skills, as well as a deep understanding of the social insurance and healthcare systems. She also has experience with self-reported survey data from patients. Prior to joining Macanda, Chantelle worked as a post-doctoral researcher investigating patient outcomes, sickness absence, and socioeconomic consequences of multiple sclerosis. She has worked throughout the research process in academia, from observational study design to the dissemination of study findings. Prior to beginning doctoral education, Chantelle was an intern in the policy team at the HTA agency of New Zealand assisting the internal implementation of their factors for consideration framework for funding decisions. Chantelle holds a BHSc (population health) and LLB (with Honours) from the University of Auckland as well as a MSc (health economics, policy, and management) and PhD (medical science) from Karolinska Institutet. Her PhD thesis “Work disability, economic situation, and societal costs of multiple sclerosis in Sweden” was defended in Spring 2022. Chantelle is also an affiliated researcher at the Division of Insurance Medicine, Dept. Clinical Neuroscience, Karolinska Institutet.

Emin has over 10 years of experience from health technology assessment and RWD studies resulting in a broad set of skills in various areas such as economic evaluations, economic modelling, reimbursement submissions, registry-based studies, literature reviews, and a deep understanding of the health care system. Prior to joining Macanda, Emin worked as a Health economist at The Dental and Pharmaceutical Benefits Agency (TLV) , Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), The Ministry of Health and Social affairs and as a commissioned researcher for the region of Västra Götaland performing large data merges and analysis. Emin has had the responsibility to assess and evaluate reimbursement submissions in many theraputical areas including orphan drugs, and also be a part of the development of FINOSE and the ongoing government assignment regarding ATMP at TLV. He has a long background in working with evidence synthesis, systematic literature reviews and transferability of economic evaluations to a Swedish setting. Emin has also had the responsibility to evaluate the cost consequences of implementing new laws to prepare the health care for the next crisis and have full responsability of large collaborating RWD projects with the pharmaceutical industry, academia and the region of Västra Götaland. Emin holds a MSc in Health economics and Public health, Sahlgrenska Academy at The University of Gothenburg.

Maria has more than 20 years of experience in Sweden from a variety of positions across Payers, Health Technology Assessment bodies and clinical value. She is a former member of the management team for the department of value-based pricing (VBP) at the Dental and Pharmaceutical Benefits Agency (TLV) and former Head of Unit [Läkemedelsenhet 1] for assessing drugs within neurology, respiratory, musculoskeletal, pain, including orphan drugs and ATMPs). Maria has a wealth of knowledge in a variety of therapeutic areas, across both hospital and prescription medications. Past positions at the TLV includes being a Senior medical assessor and Project leader. Maria has also experience from being a member of the Expert groups and the Drug- and Therapeutic committees within the Regions of Västerbotten and Jämtland. Maria holds a Masters degree in Pharmaceutical Science from Uppsala University and is a Licensed pharmacist.

August has two years of experience in Health Economics, gained both from industry and academia, while working at a small consultancy firm and for the Centre for Health Economic Research at Uppsala University. During his master's thesis, he was tasked by the Dental and Pharmaceutical Benefits Agency (TLV) to develop a method for quantifying public opinion regarding the trade-off between cost-effectiveness and disease severity in healthcare prioritization. This method was later successfully implemented by August and colleagues, in a national study at Uppsala University. Additionally, August’s exceptional aptitude for economics was recognized when he received the Uppsala Economics Association's scholarship, and his analytical abilities has consistently resulted in top academic achievements. August holds a Master’s degree in Economics from Uppsala University.